The usefulness of dapiprazole, an alpha-adrenergic blocking agent, in pigmentary glaucoma.

Abstract

The aim of this study was to increase understanding of the usefulness of an alpha-adrenergic blocking agent, dapiprazole 0.5% eyedrops, as an adjunct in antiglaucomatous therapy for 20 patients with pigmentary glaucoma receiving timolol 0.5% and pilocarpine 1%. After 12 months of dapiprazole treatment, the difference from the pretreatment mean intraocular pressure (IOP) value was statistically significant (P = .005). After 12 and 36 months of treatment, an hour-to-hour comparison of diurnal IOP curve values showed a statistically significant difference in all cases (P < .001). Although further investigations may be necessary to reach a definite conclusion, dapiprazole appeared to have a beneficial, stable in time effect in these patients.

• Authors: L Mastropasqua, P Carpineto, M Ciancaglini, P E Gallenga
• Journal: Ophthalmic surgery and lasers (Ophthalmic Surg Lasers) Vol. 27 Issue 9 Pg. 806-9 (Sep 1996) ISSN: 1082-3069 [Print] United States
• PMID: 8878205 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Adrenergic alpha-Antagonists
• Adrenergic beta-Antagonists
• Muscarinic Agonists
• Ophthalmic Solutions
• Piperazines
• Triazoles
• Pilocarpine
• dapiprazole
• Timolol

Topics

• Administration, Topical
• Adrenergic alpha-Antagonists (administration & dosage, therapeutic use)
• Adrenergic beta-Antagonists (administration & dosage, therapeutic use)
• Adult
• Aged
• Chemotherapy, Adjuvant
• Drug Therapy, Combination
• Female
• Follow-Up Studies
• Glaucoma, Open-Angle (drug therapy, physiopathology)
• Humans
• Intraocular Pressure (drug effects)
• Male
• Middle Aged
• Muscarinic Agonists (administration & dosage, therapeutic use)
• Ophthalmic Solutions
• Pilocarpine (administration & dosage, therapeutic use)
• Piperazines
• Prospective Studies
• Timolol (administration & dosage, therapeutic use)
• Treatment Outcome
• Triazoles (administration & dosage, therapeutic use)